

## **Biomolecular Life Holdings, Inc. Enters Into Marketing Services and License Agreement With Biomolecular Life LLC, Taking On Brand and Marketing Management for the Biomolecular Life Supplement Line**

Miami, Florida — Monday, August 10, 2026 — Biomolecular Life Holdings, Inc. (OTC: BIOM) ("Biomolecular" or the "Company") today announced that, effective August 7, 2026, it entered into a Marketing Services and License Agreement (the "Agreement") with Biomolecular Life LLC ("BML"), the Florida company that develops, markets, and sells the Biomolecular Life line of dietary supplement products for humans and pets. The Company furnished a supplemental disclosure statement describing the transaction through the OTC Disclosure & News Service on August 10, 2026.

### **The Agreement**

Under the Agreement, the Company becomes BML's exclusive provider of advertising and promotion management for the Biomolecular Life product line. The Company's responsibilities cover marketing strategy, the planning and placement of advertising, social media, digital and email campaigns, the development of creative materials subject to BML's approval, promotional partnerships and affiliate and influencer programs, brand management, and marketing analytics and reporting.

In consideration for the services, BML pays the Company a marketing fee equal to fifteen percent (15%) of BML's net revenue from product sales, payable quarterly within thirty days after each quarter end. The marketing fee is expected to be the Company's principal source of revenue. Third-party media, advertising, and promotional spend is budgeted in advance and funded by BML, with the Company bearing its own personnel and overhead costs. BML has also granted the Company a royalty-free license to use the Biomolecular Life brand and related marks for all branding, marketing, and promotional purposes. The initial term is one year, renewing automatically for successive one-year terms.

### **One Name Across the Brand and the Public Company**

The Agreement aligns the Company's public identity with the brand it now manages. The Company adopted the Biomolecular Life name in June 2026 and began trading under the symbol "BIOM" in July 2026; with the Agreement in place, the same name now describes both the product line and the public company responsible for marketing it. The Biomolecular Life line currently includes BIOREVIT (vitality and energy support), IMMUNO (immune system support), and MEN (active men revitalization) for people, together with a companion pet line including BIOREVIT PET, BIOIMMUNO PET, and CHON PET. The products are sold at biomolecularlife.com under the brand's signature line, "Awaken the power of the cells."

### **A First Step in a Broader Alignment**

The Agreement is structured as a beginning rather than an endpoint. Exhibit A expressly contemplates the addition of further products to the line by mutual agreement of the parties. And as described in the Company's supplemental disclosure, the Company may in the future consider a business combination with, or acquisition of, BML — a step the Agreement itself anticipates, providing that it terminates automatically upon the closing of any business combination between the parties. No agreement or binding commitment for any such transaction exists as of the date of this release, and any such transaction, if pursued, would be subject to separate disclosure and applicable requirements.

at that time, including audited financial statements of the acquired business.

"The market has watched us put the corporate house in order — the reverse split, the name change, the ticker," said Jessica Contreras, President and Chief Executive Officer of Biomolecular Life Holdings, Inc. "This Agreement is the first piece of the operating story. Biomolecular Life Holdings now runs the marketing for the brand that shares its name, and is compensated on the brand's sales. It is the beginning of the alignment between the two companies, not the end of it."

"Because I lead both companies, we treated disclosure as the first requirement rather than an afterthought," Ms. Contreras added. "The Agreement, the written consents approving it, and the risk considerations are described in the supplemental disclosure statement we furnished through OTC Markets, and the Agreement will be filed as an exhibit to our Form 10."

### **Related Party Transaction and Disclosure**

The Agreement is a related party transaction. Jessica Contreras is the sole director and principal executive officer of the Company and the sole manager of BML, and executed the Agreement on behalf of both parties, which are under common control. The Agreement was approved by written consent of each company's governing body following full disclosure of that dual role; the Company has no independent directors, and there was no independent review of the Agreement. The supplemental disclosure statement furnished on August 10, 2026, which includes a discussion of the material terms and related risk considerations, is available on the Company's disclosure page at [otcmarkets.com](http://otcmarkets.com).

### **Form 10 Registration Statement Update**

The Company continues to prepare its registration statement on Form 10, which will describe the Agreement and include it as an exhibit. Completion of the audit of the Company's financial statements is the remaining gating item for the filing. The Company expects to file the Form 10 promptly once its independent auditor completes that work, and will announce the filing when it is made.

### **About Biomolecular Life Holdings, Inc.**

Biomolecular Life Holdings, Inc., formerly known as SB Technology Holdings, Inc., is a Florida corporation that manages the advertising, marketing, branding, and promotion of the Biomolecular Life supplement line under a Marketing Services and License Agreement with Biomolecular Life LLC, and is working to reestablish itself as a fully reporting public company. The Company's common stock trades on the OTC market under the symbol "BIOM."

### **About Biomolecular Life LLC**

Biomolecular Life LLC is a privately held Florida limited liability company that develops, markets, and sells dietary supplement products for humans and pets under the Biomolecular Life brand.

### **Product Statements**

The products referenced in this release are dietary supplements. They are not intended to diagnose, treat, cure, or prevent any disease.

### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange

Act of 1934, as amended. These statements include, without limitation, statements regarding the marketing fee serving as the Company's principal source of revenue, the Company's planned marketing activities for the Biomolecular Life brand, the timing and completion of the audit of the Company's financial statements, the preparation and filing of the Company's Form 10 registration statement, the potential addition of products to the Biomolecular Life line, and the potential future consideration of a business combination with, or acquisition of, BML, for which no agreement or binding commitment exists. Actual results may differ materially from those expressed or implied. Relevant risks include, among others, the Company's dependence on a single related party for substantially all of its expected revenue, the fact that the Agreement was not negotiated at arm's length and may be terminated by either party on thirty days' notice, the absence of independent directors or independent review, and the timing and outcome of audit and regulatory review processes. The Company undertakes no obligation to update forward-looking statements except as required by law.

### **No Offer or Solicitation**

This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

### **Company Contact**

Biomolecular Life Holdings, Inc.  
1395 Brickell Ave., Suite 800, Miami, FL 33131  
Email: [info@biomolecularlife.com](mailto:info@biomolecularlife.com)  
Phone: 877-646-4833  
Website: [www.biomolecularlifeholdingsinc.com](http://www.biomolecularlifeholdingsinc.com)